SCHEMBL13301599

SCHEMBL13301599

c1ccc(N(c2ccccc2)c2ccc3c(c2)c2cc(N(c4ccccc4)c4ccc5c(c4)c4ccccc4n5-c4ccccc4)ccc2n3-c2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.60
L3MBTL1 Q9Y468 3/20 0.60
ATM Q13315 1/20 0.60
MAPK8 P45983 2/20 0.39
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 4/20 0.37
MAPT P10636 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
CYP2D6 P10635 1/20 0.37
GAA P10253 1/20 0.36
GFER P55789 1/20 0.36
KMT2A Q03164 4/20 0.36
PGR P06401 2/20 0.36
IL1R1 P14778 1/20 0.36
HPGD P15428 3/20 0.35
HTT P42858 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29374197 1.00 KDM4E (0.60) KDM4EL3MBTL1ATMMAPK8HSD17B10
SCHEMBL17085494 1.00 KDM4E (0.60) KDM4EL3MBTL1ATMMAPK8HSD17B10
SCHEMBL1979204 1.00 KDM4E (0.60) KDM4EL3MBTL1ATMMAPK8HSD17B10
SCHEMBL1103704 1.00 KDM4E (0.60) KDM4EL3MBTL1ATMMAPK8HSD17B10
SCHEMBL14032645 1.00 KDM4E (0.60) KDM4EL3MBTL1ATMMAPK8HSD17B10
SCHEMBL261333 1.00 KDM4E (0.60) KDM4EL3MBTL1ATMMAPK8HSD17B10
SCHEMBL23352493 1.00 KDM4E (0.60) KDM4EL3MBTL1ATMMAPK8HSD17B10
SCHEMBL10042885 1.00 KDM4E (0.60) KDM4EL3MBTL1ATMMAPK8HSD17B10
SCHEMBL261695 1.00 KDM4E (0.60) KDM4EL3MBTL1ATMMAPK8HSD17B10
SCHEMBL29372149 1.00 KDM4E (0.60) KDM4EL3MBTL1ATMMAPK8HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230157160-A1 COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE DUK SAN NEOLUX CO., LTD. (KR) 2023-05-18 US disclosed
US-20230157160-A1 COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE DUK SAN NEOLUX CO., LTD. (KR) 2023-05-18 US disclosed
US-11552253-B2 Compound for organic electric device, organic electric device using same, and electronic device DUK SAN NEOLUX CO., LTD. (KR) 2023-01-10 US disclosed
WO-2017095075-A1 COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING SAME, AND ELECTRONIC DEVICE 덕산네오룩스 주식회사 2017-06-08 WO disclosed
US-20100145067-A1 NOVEL CARBAZOLES DERIVATIVE AND USE THEREOF BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2010-06-10 US disclosed
US-20100145067-A1 NOVEL CARBAZOLES DERIVATIVE AND USE THEREOF BANDO CHEMICAL INDUSTRIES, LTD. (JP) 2010-06-10 US disclosed
EP-2100880-A1 NOVEL CARBAZOLE DERIVATIVE AND USE THEREOF Bando Chemical Industries, Ltd. (JP) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100145067-A1 NOVEL CARBAZOLES DERIVATIVE AND USE THEREOF GDI2, SGK2, GDI1 KDM4E 1016/4885L3MBTL1 3298/4885ATM 1735/4885
US-11552253-B2 Compound for organic electric device, organic electric device using same, and electronic device OR10J3, OR51E2, ORAI2 KDM4E 672/4885L3MBTL1 690/4885ATM 3002/4885
US-20230157160-A1 COMPOUND FOR ORGANIC ELECTRIC DEVICE, ORGANIC ELECTRIC DEVICE USING THE SAME, AND ELECTRONIC DEVICE OR10J3, OR51E2, ORAI2 KDM4E 671/4885L3MBTL1 549/4885ATM 2960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.